Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib)-Reference-Cited by-同舟云学术

Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib)

Published:2022-03-18 Issue:7 Volume:65 Page:5300-5316
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Owens Timothy D.¹^ORCID,Brameld Ken A.¹^ORCID,Verner Erik J.¹,Ton Tony¹,Li Xiaoyan¹,Zhu Jiang¹,Masjedizadeh Mohammad R.¹,Bradshaw J. Michael¹,Hill Ronald J.¹,Tam Danny¹,Bisconte Angelina¹,Kim Eun Ok¹,Francesco Michelle¹,Xing Yan¹,Shu Jin¹,Karr Dane¹,LaStant Jacob¹,Finkle David¹,Loewenstein Natalie¹,Haberstock-Debic Helena¹,Taylor Michael J.¹,Nunn Philip¹,Langrish Claire L.¹,Goldstein David M.¹

Affiliation:

1. Principia Biopharma, a Sanofi Company, 220 E Grand Ave, South San Francisco, California 94080, United States

Funder

Principia Biopharma Inc

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c01170

Reference45 articles.

1. The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy